Prasco and sanofi-aventis Sign a Distribution and Supply Agreement for Authorized Generic versions of Allegra(R) (fexofenadine HCl).

CINCINNATI -- Prasco Laboratories

--Prasco will market the Authorized Generic versions of Allegra(R) (fexofenadine HCl) Tablets in 30 mg, 60 mg, and 180 mg strengths;

--Prasco expects to capture significant share of the Fexofenadine HCl market, shipping is expected to begin the week of September 19

Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has entered into a distribution and supply agreement with Aventis Pharmaceuticals Inc. (a member of the sanofi-aventis Group) for Authorized Generic versions of the Allegra(R) (fexofenadine HCl) family of products. Prasco intends to market, in the U.S., the Authorized Generic version of Allegra (fexofenadine HCl) Tablets in 30 mg, 60 mg, and 180 mg strengths. Prasco intends to begin shipping product the week of September 19. Allegra(R) is a registered trademark of the sanofi-aventis Group.

"We are pleased to provide pharmacists and consumers with the Authorized Generic of Allegra(R)," said Prasco Chief Executive Officer E. Thomas Arington. "We are especially proud to have established this marketing relationship with sanofi-aventis, a leader in the pharmaceutical industry. Based on marketplace interest in Authorized Generics, we are optimistic that we will capture significant market share with this Authorized Generic," said Arington.

Prasco Authorized Generics

Fexofenadine HCI is the latest product from Prasco in its Authorized Generics program bringing consumers brand quality, generic priced pharmaceuticals. Prasco Authorized Generics are products produced by brand companies and marketed under the Prasco label.

About Prasco

Prasco's mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with brand sameness through Prasco Authorized Generics, which are brand-products sold under the Prasco private label. Prasco's executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company's corporate capabilities is its sales/marketing and business development teams. Prasco's product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.

The company operates from a 54,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems--including DEA-approved facilities for Schedule II-V controlled drug products.